SCHEMBL282435

SCHEMBL282435

Cc1cc(O)cc(C)c1I

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.52
CHRM1 P11229 1/20 0.52
ALOX15 P16050 1/20 0.52
MAOA P21397 1/20 0.52
TBXA2R P21731 1/20 0.52
ADRA1A P35348 1/20 0.52
HTR2B P41595 1/20 0.52
ALDH1A1 P00352 1/20 0.45
BACE1 P56817 1/20 0.41
ACHE P22303 2/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 1/20 0.37
TTR P02766 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ESR2 Q92731 4/20 0.34
ESR1 P03372 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7875531 0.86 CYP3A4 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL31618730 0.82 CYP3A4 (0.42) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL10477416 0.78 CYP3A4 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL23907108 0.77 TTR (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL27424589 0.77 ESR1 (0.40) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL28204163 0.77 CYP3A4 (0.38) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL27426711 0.77 ERN1 (0.43) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL166744 0.77 CYP3A4 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL476694 0.73 CYP3A4 (0.58) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL253926 0.73 CYP3A4 (0.58) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629382-B2 Therapy VESTLANDETS INNOVASJONSSELSKAP AS (NO) 2026-05-19 US disclosed
US-20250236760-A1 EPOXY RESIN COMPOSITION FOR ENCAPSULATING SEMICONDUCTOR DEVICE AND SEMICONDUCTOR DEVICE ENCAPSULATED USING THE SAME SAMSUNG SDI CO., LTD. (KR) 2025-07-24 US disclosed
CN-119371290-A Method for preparing deuterated phenol by copper-supported catalysis of ETS-10 zeolite 常州大学 2025-01-28 CN disclosed
CN-112867705-B Opioid receptor modulators and products and methods related thereto 埃皮欧黛公司 2024-08-20 CN disclosed
EP-3774722-B1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO EPIODYNE INC (US) 2024-07-24 EP disclosed
US-20240241444-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-07-18 US disclosed
US-20230280275-A1 PHOTOACTIVATABLE VIBRATIONAL PROBES AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY 2023-09-07 US disclosed
US-20220362265-A1 THERAPY VESTLANDETS INNOVASJONSSELSKAP AS (NO) 2022-11-17 US disclosed
EP-4021504-A1 THERAPY Vestlandets Innovasjonsselskap AS (NO) 2022-07-06 EP disclosed
US-11352316-B2 Opioid receptor modulators and products and methods related thereto EPIODYNE, INC. (US) 2022-06-07 US disclosed
CN-1882327-A Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS INC (US) 2006-12-20 CN disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
WO-2006128055-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
WO-2006086488-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-08-17 WO disclosed
EP-1689383-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2006-08-16 EP disclosed
CN-1812956-A Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN LA ROCHE (CH) 2006-08-02 CN disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 US disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 US disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 WO disclosed
US-4879398-A Process for producing 2,6-disubstituted tyrosine MONSANTO COMPANY (US) 1989-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A CYP3A4 284/4885CHRM1 847/4885ALOX15 871/4885
US-20060046980-A1 Novel phosphorus-containing thyromimetics PYGL, THRA, THOP1 CYP3A4 754/4885CHRM1 605/4885ALOX15 1968/4885
US-11352316-B2 Opioid receptor modulators and products and methods related thereto OPRM1, OPRD1, OPRK1 CYP3A4 403/4885CHRM1 32/4885ALOX15 1405/4885
US-12629382-B2 Therapy NR3C1, MGMT, GRM3 CYP3A4 1697/4885CHRM1 2047/4885ALOX15 3095/4885
US-20220362265-A1 THERAPY GRM3, GLRX3, CBR3 CYP3A4 1189/4885CHRM1 660/4885ALOX15 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.